Clinical Report: The Role of the CCL20-CCR6 Pathway in Liver Cirrhosis

Overview

This study investigates the CCL20-CCR6 axis's role in mediating interactions between mucosal-associated invariant T (MAIT) cells and M2 macrophages in liver cirrhosis. Findings suggest that this pathway contributes to immune dysregulation and fibrotic progression in cirrhosis.

Background

Cirrhosis is a critical end-stage of chronic liver disease, leading to significant morbidity and mortality globally. The interplay between immune cells, particularly MAIT cells and macrophages, is increasingly recognized as pivotal in the pathogenesis of cirrhosis. Understanding the mechanisms of immune dysregulation is essential.

Data Highlights

No numerical data or trial data available in the source material.

Key Findings

• Eight core immune genes associated with cirrhosis were identified, including CCL20.
• CCL20 was enriched in MAIT cells and linked to their activation and exhaustion profiles.
• The CCL20-CCR6 axis mediates bidirectional interactions between MAIT cells and M2 macrophages.
• Immunofluorescence confirmed the colocalization of CCL20, MAIT cells, and M2 macrophages in cirrhotic tissues.

Clinical Implications

The CCL20-CCR6 pathway may provide insights into the mechanisms of immune dysregulation in cirrhosis.

Conclusion

The study highlights the importance of the CCL20-CCR6 axis in the immune dysregulation associated with liver cirrhosis.

Related Resources & Content

1. Frontiers in Immunology, 2026 -- CCL20-CCR6 Axis Mediates Mucosal-Associated Invariant T-M2 Macrophage Crosstalk to Drive Immune Dysregulation in Liver Cirrhosis
2. Journal of Gastroenterology — Intestinal Antimicrobial Proteins: Defenders Against Hepatic Disorders
3. Journal of Gastroenterology — Stage-associated remodeling of CD169 macrophage states is linked to immune regulation in colitis-associated colorectal cancer
4. Frontiers in Immunology — Targeting macrophages in liver fibrosis
5. Frontiers in Immunology — Macrophage dysregulation in inflammatory bowel disease: cellular heterogeneity, pathogenic mechanism, and treatment
6. Management of Decompensated Cirrhosis EASL Guideline
7. Acute-on-chronic liver failure (ACLF): the ‘Kyoto Consensus’
8. https://webfiles.gi.org/GuidelineHighlights/ACGHepaticEncephGH.pdf
9. Autologous macrophage therapy for liver cirrhosis: a phase 2 open-label randomized controlled trial | Nature Medicine
10. Efruxifermin in Compensated Liver Cirrhosis Caused by MASH | New England Journal of Medicine
11. Granulocyte-colony stimulating factor (G-CSF) to treat acute-on-chronic liver failure: A multicenter randomized trial (GRAFT study) - ScienceDirect
12. Frontiers | CCL20-CCR6 Axis Mediates Mucosal-Associated Invariant T-M2 Macrophage Crosstalk to Drive Immune Dysregulation in Liver Cirrhosis
13. MAIT Cells in Liver Disease - PubMed